Company Overview and News
When it was introduced about 10 days ago the price was $40 a sector but today the airline said today it had now been cut.
Air New Zealand passengers will be able to access Wi-Fi on international flights — for a chunky price.
Air New Zealand will celebrate the royal wedding of Prince Harry and Meghan Markle by offering free lounge access to passengers who share the same wedding date.
Blackstone funds have struck a $635 million deal to buy seven big central Auckland office blocks, subject to Overseas Investment Office and land owner approval, the vendor has announced.
Just over 5 per cent of passengers fly business class or better but they provide nearly a third of annual global revenue for airlines which totals $1.1 trillion.
Last year there was just one initial public offering on the New Zealand Stock Exchange's main board versus eight de-listings — despite the local sharemarket having otherwise enjoyed a record-breaking 12 months.
It's time to reconvene the Capital Markets Taskforce and have a clear look at whether more state assets can be primed for partial privatisation through the mixed-ownership model (MOM) and beef up liquidity at the NZX.
Air New Zealand is considering restoring flights to Wānaka as part of a plan to grow its regional network by 20 per cent during the next five years.
An MSCI index reshuffle sent shares for Fletcher Building soaring after it survived, but Mercury Energy shares fell as it was culled from the index.
New Zealand shares dipped from a record high, with Air New Zealand and Mercury New Zealand falling while Synlait Milk and Fletcher Building gained.
Travel agents say they received the news from the airline yesterday - and today the airline confirmed it could no longer absorb extra costs.
Southwest Airlines reported year-over-year April 2018 traffic with revenue passengers miles falling (0.3%) despite available seat miles increasing 1.5% year-over-year.
The airline has taken space in a secure building near its downtown Auckland headquarters to develop new seats for its business premier class, timed for fitting into its next generation of long-haul planes early next decade, and for retrofitting into the aircraft that remain in its fleet.
It will be the first time the airline uses the new generation aircraft on flights to this country and it will replace a Boeing 777-200 that has been used on the route. The airline flies daily, year round.
Martin Snedden has a new mission. The man who ran New Zealand's hosting of the Rugby World Cup in 2011 wants to save Auckland.
7h - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...
8h - Asif
BUSINESS TrovaGene is a clinical-stage, precision medicine oncology therapeutics company. The company's primary focus is to develop oncology therapeutics for improved cancer care and to optimize drug development by leveraging its proprietary Precision Cancer Monitoring® (“PCM”) technology in tumor genomics. The company's lead drug candidate, PCM-075, is a Polo-like Kinase 1 (“PLK1”) selective adenosine triphosphate (“ATP”) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and synergy in combination with more than ten different chemotherapeutics and targeted therapies, such as Zytiga® (abiraterone acetate), Beleodaq® (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade® (bortezomib) in Acute Myeloid Leukemia (“AML”), metastatic Castration-Resistant Prostate Cancer (“mCRPC”) and other hematologic and solid tumor cancers. On March 15, 2017, the company announced the licensing of PCM-075, a PLK1 inhibitor...
2018-05-19 - Asif
OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...
as of ET